Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
2022 · Molecular Cancer · 90 citations
https://doi.org/10.1186/s12943-022-01536-6
Z
Zhonghua Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
107
Papers
2.1K
Citations
24
h-index
37
i10-index
Zhonghua Wang is an academic researcher from Shanghai Medical College of Fudan University. The author has contributed to research in topics: Cancer Treatment and Pharmacology & HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies. The author has an h-index of 24, co-authored 91 publications.
ORCID: 0000-0001-8792-3753Papers by this author
worksFamitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
2022 · Clinical Cancer Research · 89 citations
https://doi.org/10.1158/1078-0432.ccr-21-4313
In situ metabolomics in nephrotoxicity of aristolochic acids based on air flow-assisted desorption electrospray ionization mass spectrometry imaging
2019 · Acta Pharmaceutica Sinica B · 85 citations
https://doi.org/10.1016/j.apsb.2019.12.004
Risk and prognostic factors of breast cancer with liver metastases
2021 · BMC Cancer · 62 citations
https://doi.org/10.1186/s12885-021-07968-5
Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid
2011 · BMC Cancer · 19 citations
https://doi.org/10.1186/1471-2407-11-403
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer
2024 · BMC Cancer · 11 citations
https://doi.org/10.1186/s12885-024-12892-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat